Gastroparesis Treatment Products Market Size, Share, Growth, and Industry Analysis, By Type (Drugs and Surgical Treatment Products), By Application (Hospital Pharmacies, Private Clinics, Drug Stores and E-Commerce), Regional Insights and Forecast to 2031

Updated On: 29 April 2024

GASTROPARESIS TREATMENT PRODUCTS MARKET REPORT OVERVIEW

• 

• to learn more about this report

The global gastroparesis treatment products market size was USD 5923 million in 2022 and the market is projected to touch 7585.8 million by 2028, exhibiting a CAGR of 4.2% during the forecast period.

The Gastroparesis Treatment Products market has witnessed significant growth in recent years, driven by the rising prevalence of gastroparesis, advancements in treatment options, and increasing awareness among patients and healthcare professionals. Gastroparesis is a condition characterized by delayed gastric emptying due to impaired motility of the stomach muscles, leading to symptoms such as nausea, vomiting, abdominal pain, and early satiety. Several treatment options are available for managing gastroparesis, including medications, dietary modifications, medical devices, and surgical interventions. The market for gastroparesis treatment products encompasses a wide range of pharmaceuticals and devices designed to alleviate symptoms and improve gastric motility.

Pharmaceuticals play a crucial role in managing gastroparesis symptoms and improving gastrointestinal motility. Prokinetic agents such as metoclopramide, domperidone, and erythromycin are commonly prescribed to enhance gastric emptying and reduce symptoms. Additionally, antiemetic medications like ondansetron and promethazine are prescribed to alleviate nausea and vomiting associated with gastroparesis. In recent years, there has been growing interest in novel treatment approaches for gastroparesis, including botulinum toxin injections, gastric electrical stimulation (GES) devices, and emerging pharmacotherapies targeting novel pathways involved in gastric motility regulation. GES devices such as Enterra Therapy and Gastric Electrical Stimulation System have shown promising results in improving gastric emptying and symptom management in patients with refractory gastroparesis.

COVID-19 Impact: Market Growth Restrained by Pandemic due to Supply Chain Disruptions

The global COVID-19 pandemic has been unprecedented and staggering; with the gastroparesis treatment products market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to market’s growth and demand returning to pre-pandemic levels.

The pandemic disrupted global supply chains, leading to shortages and delays in the availability of pharmaceuticals, medical devices, and nutritional supplements used in gastroparesis management. Patients may have encountered difficulties in accessing essential medications or experienced interruptions in their treatment regimens due to supply chain constraints. The pandemic led to disruptions in routine healthcare services, including outpatient visits, elective procedures, and diagnostic tests. Many patients with gastroparesis experienced delays in accessing specialized care, leading to challenges in disease management and treatment optimization.

Clinical trials investigating novel therapies for gastroparesis faced disruptions due to enrollment challenges, site closures, and regulatory delays imposed by the pandemic. The slowdown in research activities could delay the development and regulatory approval of innovative treatment products, affecting the pipeline of new therapies for gastroparesis. The market is anticipated to boost the gastroparesis treatment products market growth following the pandemic.

LATEST TRENDS

"Technological Innovations in Medical Devices to Drive Market Growth"

The development of innovative medical devices for gastroparesis management continues to evolve. This includes advancements in gastric electrical stimulation (GES) devices, intragastric balloons, and other implantable devices designed to modulate gastric motility and alleviate symptoms in patients with refractory gastroparesis.

Digital health technologies such as mobile applications, wearable devices, and remote monitoring platforms are being integrated into gastroparesis management to enhance patient engagement, facilitate self-management, and enable real-time data tracking. These technologies offer opportunities for remote symptom monitoring, medication adherence tracking, and virtual consultations, thereby improving access to care and enhancing treatment outcomes. These latest developments are anticipated to boost the gastroparesis treatment products market share.

GASTROPARESIS TREATMENT PRODUCTS MARKET SEGMENTATION

• 

• to learn more about this report

• By Type

Based on type the global market can be categorized into Drugs and Surgical Treatment Products.

Drugs: These drugs promote gastrointestinal motility and are commonly used to accelerate gastric emptying in patients with gastroparesis. Examples include metoclopramide, domperidone, and erythromycin. Patients with gastroparesis may experience abdominal pain, for which pain medications such as opioids and non-steroidal anti-inflammatory drugs (NSAIDs) are sometimes prescribed.

Surgical Treatment Products: Gastric Electrical Stimulation (GES) Devices, these implantable devices deliver electrical stimulation to the stomach to modulate gastric motility and alleviate symptoms of gastroparesis. GES devices such as Enterra Therapy and Gastric Electrical Stimulation System have been approved for use in patients with refractory gastroparesis. Pyloroplasty is a surgical procedure that involves enlarging and/or opening the pyloric sphincter at the outlet of the stomach to improve gastric emptying. It is sometimes performed in conjunction with other surgical interventions for gastroparesis.

• By Application

Based on application the global market can be categorized into Hospital Pharmacies, Private Clinics, Drug Stores and E-Commerce.

Hospital Pharmacies: Hospital pharmacies play a vital role in the distribution of Gastroparesis Treatment Products within healthcare facilities. They stock a wide range of pharmaceuticals, medical devices, and nutritional supplements used in the management of gastroparesis. Healthcare providers, including gastroenterologists, internal medicine specialists, and dietitians, prescribe gastroparesis treatment products to patients during hospital visits or inpatient stays.

Private Clinics:

Private clinics, including gastroenterology clinics and specialized treatment centers, provide outpatient care and consultation services for individuals with gastroparesis.

Gastroenterologists and other healthcare providers in private clinics evaluate patients with gastroparesis, diagnose the condition, and develop personalized treatment plans tailored to individual patient needs.

Private clinics stock and dispense gastroparesis treatment products, including prescription medications, nutritional supplements, and medical devices, to patients for at-home management of symptoms and disease progression.

Drug Stores: Drug stores, including retail pharmacies and community pharmacies, serve as accessible points of care for individuals seeking over-the-counter (OTC) medications and nutritional supplements for gastroparesis symptom management. Patients with gastroparesis may purchase OTC medications such as antiemetics, digestive aids, and dietary supplements from drug stores to alleviate symptoms such as nausea, vomiting, and bloating.

E-Commerce: E-commerce platforms offer a convenient and accessible channel for purchasing Gastroparesis Treatment Products online, including prescription medications, medical devices, and nutritional supplements. Patients with gastroparesis can browse and purchase a wide range of treatment products from online pharmacies, specialty healthcare retailers, and e-commerce marketplaces without leaving their homes.

DRIVING FACTORS

"Increasing Prevalence of Gastroparesis to Boost the Market"

The rising prevalence of gastroparesis, attributed to factors such as diabetes, post-surgical complications, neurological disorders, and idiopathic causes, drives the demand for effective treatment options. As the incidence of gastroparesis continues to rise globally, there is a growing need for innovative therapies to address the unmet medical needs of affected individuals. Diabetes mellitus, particularly type 1 and type 2 diabetes, is a leading cause of gastroparesis. The growing prevalence of diabetes globally contributes to an increased incidence of gastroparesis cases, thereby fueling the demand for gastroparesis treatment products. Pharmaceutical companies focus on developing medications targeting diabetic gastroparesis, addressing a significant unmet medical need in this patient population.

"Advancements in Treatment Options to Expand the Market"

Ongoing research and development efforts in the field of gastroenterology lead to advancements in treatment options for gastroparesis. Pharmaceutical companies and medical device manufacturers invest in developing novel medications, medical devices, and therapeutic interventions aimed at improving gastric motility, alleviating symptoms, and enhancing quality of life for patients with gastroparesis. Technological advancements play a crucial role in driving innovation in gastroparesis treatment products. The development of advanced medical devices such as gastric electrical stimulation (GES) devices, intragastric balloons, and minimally invasive surgical techniques expands the treatment armamentarium for gastroparesis management. Additionally, digital health solutions, including mobile applications, wearable devices, and remote monitoring platforms, enhance patient engagement and facilitate remote symptom monitoring and management. These factors are anticipated to drive the gastroparesis treatment products market share.

RESTRAINING FACTOR

"Adverse Effects and Safety Concerns to Potentially Impede Market Growth"

Pharmacological treatments for gastroparesis, such as prokinetic agents and antiemetics, are associated with various adverse effects, including extrapyramidal symptoms, cardiac arrhythmias, and gastrointestinal disturbances. Safety concerns surrounding the long-term use of these medications may deter patients and healthcare providers from pursuing pharmacotherapy as a primary treatment option. Similarly, surgical interventions and implantable devices carry risks of complications and adverse events, impacting their adoption and utilization in clinical practice. The factors are anticipated to hinder the growth of the gastroparesis treatment products market growth.

GASTROPARESIS TREATMENT PRODUCTS MARKET REGIONAL INSIGHTS

• 

• to learn more about this report

"North America is Dominating the Market with Advanced Healthcare Infrastructure"

The market is primarily segmented into Europe, Latin America, Asia Pacific, North America, and Middle East & Africa.

North America boasts advanced healthcare infrastructure with well-established healthcare systems, specialized medical facilities, and a robust network of healthcare providers. This facilitates timely diagnosis, comprehensive disease management, and access to a wide range of gastroparesis treatment products, including pharmaceuticals, medical devices, and surgical interventions. The region is at the forefront of technological innovation in healthcare, driving advancements in gastroparesis treatment products. Pharmaceutical companies, medical device manufacturers, and research institutions in North America invest significantly in research and development efforts aimed at developing novel medications, medical devices, and therapeutic interventions for managing gastroparesis.

KEY INDUSTRY PLAYERS

"Key Players Focus on Partnerships to Gain a Competitive Advantage "

Prominent market players are making collaborative efforts by partnering with other companies to stay ahead in the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolio.

List of Market Players Profiled

• Sumitomo [Japan]
• Cadila Pharmaceuticals [India]
• Sanofi [France]
• Teva [Israel]
• Johnson & Johnson [U.S.]

INDUSTRIAL DEVELOPMENT

November 2021: Enterra Therapy is an implantable gastric electrical stimulation (GES) system designed to treat symptoms of gastroparesis, a condition characterized by delayed gastric emptying due to impaired motility of the stomach muscles. Developed by Medtronic, Enterra Therapy consists of a neurostimulator device surgically implanted in the abdominal wall and connected to electrodes placed on the gastric muscle wall.

REPORT COVERAGE

The study encompasses a comprehensive SWOT analysis and provides insights into future developments within the market. It examines various factors that contribute to the growth of the market, exploring a wide range of market categories and potential applications that may impact its trajectory in the coming years. The analysis takes into account both current trends and historical turning points, providing a holistic understanding of the market's components and identifying potential areas for growth.

The research report delves into market segmentation, utilizing both qualitative and quantitative research methods to provide a thorough analysis. It also evaluates the impact of financial and strategic perspectives on the market. Furthermore, the report presents national and regional assessments, considering the dominant forces of supply and demand that influence market growth. The competitive landscape is meticulously detailed, including market shares of significant competitors. The report incorporates novel research methodologies and player strategies tailored for the anticipated timeframe. Overall, it offers valuable and comprehensive insights into the market dynamics in a formal and easily understandable manner.